Lazard, Inc. (LAZ)
(Delayed Data from NYSE)
$38.68 USD
-0.27 (-0.69%)
Updated May 10, 2024 04:00 PM ET
After-Market: $38.67 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LAZ 38.68 -0.27(-0.69%)
Will LAZ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LAZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LAZ
Lazard (LAZ) Dips 1% Despite Surpassing Q1 Earnings Estimates
Compared to Estimates, Lazard (LAZ) Q1 Earnings: A Look at Key Metrics
LAZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lazard (LAZ) Surpasses Q1 Earnings and Revenue Estimates
Analysts Estimate LendingClub (LC) to Report a Decline in Earnings: What to Look Out for
Lazard (LAZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for LAZ
Lazard Reports April 2024 Assets Under Management
Lazard reports a 3.8% M/M fall in AUM
Lazard reports preliminary AUM of $240.8B as of April 30
Lazard Welcomes Michele Colocci as Vice Chairman, Investment Banking and Managing Director, Healthcare
Analyst Favorites With Strong Buyback Activity: Lazard Ranks As a Top Pick